Company history

Ajinomoto’s origins reach back to 1888, when Suzuki Naka started an iodine-manufacturing family business in Hayama, Kanagawa. The immediate motive was hard-nosed — rebuilding the household finances after the sudden death of the first Suzuki Saburosuke and a failed market speculation by the second. Under technical guidance from Nagai Nagayoshi, a professor at Tokyo Imperial University, the iodine trade grew into a pharmaceutical business and became the pillar that supported the Suzuki family — and, later, the capital base from which a wholly new venture was launched. In 1908 Ikeda Kikunae, also of Tokyo Imperial University, identified the source of the savoury taste in kelp as glutamate; the large firms of the day passed on commercialising it as too hard to industrialise, and it was the second Suzuki Saburosuke who took it on, running the existing iodine business in parallel to wall off the risk of an uncertain new business.

Household Aji-no-moto seasoning went on sale in May 1909. After environmental disputes with neighbours at the Zushi plant, Ajinomoto completed a move to a Kawasaki plant by 1914 and reached true mass production. Its original wholesale buyer, Nippon Shoyu Jozo, went bankrupt in a 1910 saccharin scandal, forcing Ajinomoto to build a sales channel of its own. From bases in Tokyo and Osaka it developed a regional sole-agent (tokuyakuten) system through the late 1910s and 1920s, layering sub-agents and retailers beneath each agent — a distinctive network that delivered price control and distribution control at the same time.

Kawasaki mass production joined to a national agent network left latecomers almost no way into the strong channels, and Ajinomoto’s dominance of the monosodium-glutamate market was fixed for decades, from the 1920s into the 1950s. Yet holding that network together required supplying more than a single condiment: agents needed a broader line of goods to carry, so the pull toward becoming a comprehensive foods company came as much from the distribution side as from technology. That double premise — a near-monopoly in seasoning, and a structural need to widen the product range — was carried, unresolved, into the decades that followed.

In 1956 Kyowa Hakko announced monosodium glutamate made by direct fermentation, and the extraction-method advantage that had underpinned Ajinomoto’s edge suddenly wavered. The trade press treated fermentation as an invention that overturned the old process, a view that Ajinomoto was heading into decline spread through the market, and the share price fell. Ajinomoto chose not to take the technical conflict to court: it contracted to buy Kyowa’s entire MSG output and so headed off the disruption, with Asahi Breweries president Yamamoto Tamesaburo brokering the deal and the two firms moving from rivalry to cooperation and, later, cross-licensing. The episode drove home how dangerous it was to depend on a single technology — and became the spark for diversification.

Aware now of how fragile an MSG-only earnings model was, Ajinomoto set out to widen its business and steady its returns. In 1963 an international tie-up with Corn Products of the United States created Knorr Foods, carrying Ajinomoto into processed foods on the back of soups, and an alliance pattern — an outside brand joined to Ajinomoto’s own channel — became its basic template. Management stated the task plainly: to turn a single-product Ajinomoto into a comprehensive foods company. From 1966 it added direct dealing with the fast-growing supermarkets alongside the agent system, and by 1970 the trade press was describing its ever-widening range as a “dinner-table encirclement.”

From the 1960s Ajinomoto built plants overseas, starting in Southeast Asia, with amino-acid fermentation at the core, and by the early 2000s feed-grade amino acids such as lysine had become one of its pillar businesses — even as expanded supply from Korea’s CJ CheilJedang sharpened price competition and made a volume-driven model volatile. The comprehensive-foods result had limits at home, too: in 1983 MSG still held about 60 per cent of the domestic market, yet Ajinomoto’s profit growth since 1965 ranked near the bottom among major food firms, and by the 1990s it trailed Kewpie in mayonnaise and Nisshin Oil in cooking oil, with no decisive top brand outside seasoning. Against that backdrop the most consequential move was a quiet one: in 1998 Ajinomoto set up a specialist subsidiary and concentrated resources on ABF, an insulating film for semiconductor packaging derived from its amino-acid research. Cut loose from the food business’s decision cycle and adopted again and again by Intel, ABF grew into a very high-margin business technically continuous with the company’s core science.

In 2003 Ajinomoto moved its oils-and-fats business into J-Oil Mills, formed by merging it with Honen Corporation and Yoshihara Oil Mill. The year before, the trade press had noted that the domestic food business — more than half of consolidated sales — was being squeezed as retail discounting became permanent, with a frozen-foods restructuring still unresolved on the books. The portfolio assembled in the name of comprehensive foods had turned into a drag on core earnings as retailers gained the upper hand on price, and it was no longer a problem Ajinomoto could solve by extending the same comprehensive-foods logic.

Faced with chronic low returns and oversupply in domestic oils, Ajinomoto chose horizontal integration as a means of exit — a rare manoeuvre in the food industry at the time — placing the business in a new company and withdrawing its own capital. Pulling invested capital out of a structurally low-return field and freeing it for redeployment was a genuine shift of thinking, and it later stood out in the company’s memory as the practical precedent for treating retreat as an ordinary tool. This experience became an important stepping-stone toward the capital-efficiency management Ajinomoto would adopt years later.

The strain did not ease. Overseas, feed-amino-acid price competition with CJ continued, forcing a restructuring in 2011 as earnings fell; at home and abroad the group kept expanding by acquisition, taking in the United States frozen-foods maker Windsor Quality in 2014. The portfolio went on growing while the return on the capital tied up in it went, for the most part, unmeasured — the tension that the next decade would finally force into the open.

In the year ended March 2019 Ajinomoto booked impairment losses of about $286.2M (¥31bn), centred on its overseas food business. Consolidated sales rose while profit fell, and a structural problem surfaced in the numbers: through the 2010s capital had been allocated in favour of top-line growth without adequately verifying that the money invested was being earned back. It was a symbolic set of results — the negative side of comprehensive diversification concentrated into a single reckoning.

The response was a change of management system. In 2019 Ajinomoto placed ROIC at the centre of how it runs the company, calculating it business by business against the cost of capital and writing a rule into the organisation: being “technically right” or “socially meaningful” would no longer, on its own, justify holding capital in a business. Low-return units now had to answer on capital efficiency rather than future promise. That same year, though profitable, the company carried out 144 voluntary redundancies among managers aged 50 and over — institutionalising as routine what Japanese firms had long treated as a crisis measure, and signalling how far it meant to redesign its fixed-cost base.

The turns came quickly after that. In 2023 Ajinomoto scrapped its conventional three-year plan for “medium-term ASV management,” backcast from the company it wants to be in 2030, after president Taro Fujie diagnosed the old method as a “mid-plan disease”; it recast successive price increases as “value pricing,” an offensive strategy rather than a defensive one; and it stepped into gene-therapy contract manufacturing by acquiring the United States firm Forge Biologics for about $1.4B (¥200bn), choosing healthcare, under the banner of AminoScience, as a non-food earnings pillar to stand beside ABF. Yet the acquire-the-technology playbook stumbled early: Ajinomoto Althea, an earlier United States bio-pharma purchase, booked restructuring costs and an impairment. Whether Ajinomoto — which has swung its post-fermentation diversification from patient in-house cultivation to large acquisitions — can grow healthcare into a business to rival ABF is not yet clear.